---
layout: default
title: Triclofos
parent: Model Prediction Only (L5)
nav_order: 856
evidence_level: L5
indication_count: 10
---

# Triclofos
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

Using the drug-repurposing-evaluation-report skill implicitly per the specified template (no other skill applies — this is a direct content-generation task using the fixed prompt format).

# Triclofos: From Sedative-Hypnotic Agent to Insomnia

## One-Sentence Summary

> Triclofos is the prodrug of trichloroethanol — the same active metabolite as chloral hydrate — and has historically been used as a sedative-hypnotic, though it is not currently marketed or registered in India.
> The TxGNN model's top prediction for this drug is **Insomnia (disease)**, essentially reaffirming its known historical pharmacological role rather than identifying a truly novel indication.
> Direct supporting evidence for this exact entry is currently limited (0 clinical trials, 0 literature citations attached to the "insomnia" node itself), though closely related synonym terms and adjacent indications (sleep disorder, anxiety/sedation) are supported by multiple older RCTs and case reports.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No structured registration or indication data available (drug not currently marketed in India; original MOA and indication fields are data gaps) |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 (mechanism/preclinical-level support) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacology, Triclofos (triclofos sodium) is a phosphorylated derivative of chloral hydrate, functioning as a prodrug that is metabolized to trichloroethanol — the identical active metabolite produced by chloral hydrate itself. Trichloroethanol acts on the GABA-A receptor complex, producing sedative and hypnotic effects, a mechanism that is well established in the pharmacology literature even though it is not recorded in the structured `original_moa` field here.

Because trichloroethanol is the shared active moiety of both chloral hydrate and triclofos, and chloral hydrate has a long clinical history as a sedative-hypnotic, the predicted indication of "insomnia" is not so much a novel repurposing hypothesis as a restatement of the drug's traditional pharmacological class effect. This is corroborated by literature attached to the closely related synonym node "sleep disorder, initiating and maintaining sleep," which includes a 1979 double-blind crossover hypnotic trial (PMID 387491) directly comparing triclofos sodium to nitrazepam for insomnia, and a 1972 case-series report (PMID 4567567) titled "Triclofos sodium (Triclos) for insomnia."

Additional indirect support comes from a substantial body of pediatric procedural-sedation and premedication RCTs (attached to the "anxiety" node) comparing oral triclofos to midazolam, diazepam, flunitrazepam, and hydroxyzine. These studies confirm triclofos's clinically effective sedative-hypnotic activity across decades of use, even though their endpoints (procedural sedation, preoperative anxiolysis) are not identical to a chronic insomnia indication. Overall, the mechanistic rationale is strong, but it should be read as validating an already-known drug class effect rather than uncovering a new therapeutic use.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available for this specific indication entry (insomnia). Note: closely related synonym terms in this evidence pack (e.g., "sleep disorder, initiating and maintaining sleep") do carry supporting literature — see the rationale discussion above.

---

## India Market Information

Triclofos currently has no registered products in India — 0 authorizations are on record, and market status is listed as **Not Marketed**.

---

## Safety Considerations

Please refer to the package insert for safety information. Structured warnings, contraindications, and drug-interaction data are not currently available for this entry, and this gap has been flagged as **Blocking** (DG001) for safety evaluation purposes — see Conclusion below.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The predicted indication is well-supported mechanistically (shared active metabolite with chloral hydrate, a known hypnotic class effect) and consistent with historical literature, but this evidence pack lacks any registered product, label warnings/contraindications, or trials/literature directly attached to the insomnia entry itself. A blocking data gap (missing warnings/contraindications) prevents a preliminary safety assessment (S1), so the candidate cannot advance past a research question stage yet.

**To proceed, the following is needed:**
- Official label warnings and contraindications (via source regulatory agency, since India has no registration to reference)
- Confirmed mechanism of action data from DrugBank
- Clarification of current global marketing/registration status for triclofos
- A safety monitoring plan addressing known chloral-hydrate-class risks (hepatic metabolism, respiratory depression, cardiac arrhythmia with prolonged/high-dose use), particularly given its historical use in pediatric populations
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

